Combination therapy of TKI and IB may be of benefit in the treatment of CML as well as other ROS-driven hematopoietic malignancies with driver oncogenic fusions and associated genomic instability, through targeting NADPH oxidase. The gene discussed is FMO5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.